Haploidentical Stem Cell Transplantation
The feasibility of stem cell transplantation across the major histocompatibility (MHC) barrier—as in haploidentical stem cell transplantation (SCT)—has been proved for some time in several studies. the main limitations include a higher graft failure rate, delayed immune reconstitution after transpla...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2012-04-01
|
Series: | Hematology/Oncology and Stem Cell Therapy |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1658387612500154 |
id |
doaj-547eff7f4da14acab086b9718f8acef5 |
---|---|
record_format |
Article |
spelling |
doaj-547eff7f4da14acab086b9718f8acef52020-11-25T02:13:58ZengElsevierHematology/Oncology and Stem Cell Therapy1658-38762012-04-01527383Haploidentical Stem Cell TransplantationAmr Ahmed Nassar0Amr Ahmed Nassar ∙ King Abdulaziz Medical City, Mecca, Saudi Arabia; King Abdullah Medical City, Mecca, Western Province, Saudi ArabiaThe feasibility of stem cell transplantation across the major histocompatibility (MHC) barrier—as in haploidentical stem cell transplantation (SCT)—has been proved for some time in several studies. the main limitations include a higher graft failure rate, delayed immune reconstitution after transplantation with high rates of life-threatening infections, a higher incidence of post-transplant lymphoproliferative disease (PTLPD), and severe acute and chronic graft-versus-host disease (GVHD). In an attempt to reduce the transplant-related morbidity/mortality, several techniques had been evaluated involving conditioning regimen intensity, graft engineering, post-transplant cellular therapy and immunosuppression. this review will describe the current situation. it will also discuss initiatives and strategies to overcome the limitations associated with transplant across the MHC barrier.http://www.sciencedirect.com/science/article/pii/S1658387612500154 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Amr Ahmed Nassar |
spellingShingle |
Amr Ahmed Nassar Haploidentical Stem Cell Transplantation Hematology/Oncology and Stem Cell Therapy |
author_facet |
Amr Ahmed Nassar |
author_sort |
Amr Ahmed Nassar |
title |
Haploidentical Stem Cell Transplantation |
title_short |
Haploidentical Stem Cell Transplantation |
title_full |
Haploidentical Stem Cell Transplantation |
title_fullStr |
Haploidentical Stem Cell Transplantation |
title_full_unstemmed |
Haploidentical Stem Cell Transplantation |
title_sort |
haploidentical stem cell transplantation |
publisher |
Elsevier |
series |
Hematology/Oncology and Stem Cell Therapy |
issn |
1658-3876 |
publishDate |
2012-04-01 |
description |
The feasibility of stem cell transplantation across the major histocompatibility (MHC) barrier—as in haploidentical stem cell transplantation (SCT)—has been proved for some time in several studies. the main limitations include a higher graft failure rate, delayed immune reconstitution after transplantation with high rates of life-threatening infections, a higher incidence of post-transplant lymphoproliferative disease (PTLPD), and severe acute and chronic graft-versus-host disease (GVHD). In an attempt to reduce the transplant-related morbidity/mortality, several techniques had been evaluated involving conditioning regimen intensity, graft engineering, post-transplant cellular therapy and immunosuppression. this review will describe the current situation. it will also discuss initiatives and strategies to overcome the limitations associated with transplant across the MHC barrier. |
url |
http://www.sciencedirect.com/science/article/pii/S1658387612500154 |
work_keys_str_mv |
AT amrahmednassar haploidenticalstemcelltransplantation |
_version_ |
1724902936154210304 |